[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][=Branch1][C][=O][O][C@H1][C@H1][Branch2][Ring2][=N][C][C@@H1][C@@][Ring1][Branch1][Branch2][Ring2][Ring2][C][C][C@H1][C@H1][Ring1][=Branch1][C][C][C@@H1][C@@][Ring1][=Branch1][Branch2][Ring1][Ring2][C][C@@H1][Branch1][Branch2][C@H1][Branch1][Ring2][C][Ring1][=Branch1][O][N][C][C][O][C][C][Ring1][=Branch1][C][C][N+1][Branch1][#Branch1][C][C][C][C][Ring1][Branch1][C][C][=C]"}, {"from": "gpt", "value": "The molecule is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. [Sugammadex] is a \u03b3-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium."}]